These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14428956)

  • 21. [Antigen of Mycobacterium tuberculosis and specificity].
    PANISSET MM
    Union Med Can; 1952 Sep; 81(9):1081-7. PubMed ID: 13039111
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biologic effects of isoniazid].
    FREERKSEN E
    Beitr Klin Tuberk Spezif Tuberkuloseforsch; 1953; 110(1-2):97-106. PubMed ID: 13140095
    [No Abstract]   [Full Text] [Related]  

  • 23. ISONIAZID trials.
    Lancet; 1952 Sep; 2(6732):471-2. PubMed ID: 14956048
    [No Abstract]   [Full Text] [Related]  

  • 24. Type-1 polarised dendritic cells are a potent immunogen against
    Satake Y; Nakamura Y; Kono M; Hozumi H; Nagata T; Tsujimura K; Enomoto N; Fujisawa T; Inui N; Fujiyama T; Tokura Y; Matsui T; Yokomura K; Shirai M; Hayakawa H; Suda T
    Int J Tuberc Lung Dis; 2017 May; 21(5):523-530. PubMed ID: 28399967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunological differentiation of the antigens of Mycobacterium tuberculosis (Tb.1*) culture filtrate and comparison with the extracts of other Mycobacterium strains].
    Göing H; Heymann G; Kaiser P; Siefert G
    Beitr Klin Erforsch Tuberk Lungenkr; 1966; 134(3):191-206. PubMed ID: 4960966
    [No Abstract]   [Full Text] [Related]  

  • 26. [Studies on double or triple resistance of Mycobacterium tuberculosis. 1. The rate of appearance of double or triple resistance, and the effect of drugs on the appearance of this resistance].
    KUROIWA K
    Kekkaku; 1960 Jul; 35():492-8. PubMed ID: 13755309
    [No Abstract]   [Full Text] [Related]  

  • 27. [The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice].
    Zabolotnykh NV; Vinogradova TI; Stukova MA; Vasil'eva SN; Vitovskaia ML; Egorov AIu
    Probl Tuberk Bolezn Legk; 2008; (12):30-4. PubMed ID: 19230185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of in vitro and in vivo released antigens of diagnostic interest in Mycobacterium tuberculosis by immunoblotting.
    Shende N; Gupt S; Upadhye V; Kumar S; Harinath BC
    Indian J Exp Biol; 2008 Jan; 46(1):18-21. PubMed ID: 18697566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Orientation on the antituberculotic rimifon].
    FUST B
    Schweiz Z Tuberk; 1953; 10(1):56-60. PubMed ID: 13048642
    [No Abstract]   [Full Text] [Related]  

  • 30. [Experiences of six years with the combined treatment of tuberculosis with bacteriostatics (conteben, isoniazid, streptomycin) and specific substances (tebeprotin, phthioic acid phosphatide)].
    TOENNIESSEN E
    Munch Med Wochenschr; 1954 Apr; 96(17):490-2. PubMed ID: 13165582
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis.
    Lv H; Gao Y; Wu Y; Zhai M; Li L; Zhu Y; Liu W; Wu Z; Chen F; Qi Y
    Immunol Lett; 2010 Oct; 133(2):94-8. PubMed ID: 20705101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of vaccine research and development: tuberculosis.
    Girard MP; Fruth U; Kieny MP
    Vaccine; 2005 Dec; 23(50):5725-31. PubMed ID: 16153751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isonicotinic acid hydrazide.
    SUPNIEWSKI J
    Przegl Lek; 1952; 8(8):215-20. PubMed ID: 13027430
    [No Abstract]   [Full Text] [Related]  

  • 34. [Possibilities in the field of new anti-tuberculosis drugs].
    MASCHERPA P
    G Ital Chemioter; 1954; 1(3-4):340-65. PubMed ID: 14391648
    [No Abstract]   [Full Text] [Related]  

  • 35. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens.
    Broxmeyer L; Sosnowska D; Miltner E; Chacón O; Wagner D; McGarvey J; Barletta RG; Bermudez LE
    J Infect Dis; 2002 Oct; 186(8):1155-60. PubMed ID: 12355367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Observation of resistance of m. tuberculosis against rimiform in a patient treated with this drug; preliminary communication].
    NIGOGHOSSIAN GA
    Schweiz Med Wochenschr; 1952 Jul; 82(27):707. PubMed ID: 14950251
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of serologic and cell-mediated reactivity of a 38-kDa antigen isolated from Mycobacterium tuberculosis.
    Kadival GV; Chaparas SD; Hussong D
    J Immunol; 1987 Oct; 139(7):2447-51. PubMed ID: 2443566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Retarded appearance of resistant Mycobacteria tuberculosis during treatment with the combined preparation dipasic].
    SCHAUB R
    Beitr Klin Tuberk Spezif Tuberkuloseforsch; 1956; 115(5):409-11. PubMed ID: 13341840
    [No Abstract]   [Full Text] [Related]  

  • 39. A 38-kD Mycobacterium tuberculosis antigen associated with infection. Its isolation and serologic evaluation.
    Espitia C; Cervera I; González R; Mancilla R
    Clin Exp Immunol; 1989 Sep; 77(3):373-7. PubMed ID: 2478322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation of a highly potent hemagglutinating antigen of M. tuberculosis.
    AOKI Y; NAGAI K; WATANABE T
    Am Rev Respir Dis; 1961 Dec; 84():907-10. PubMed ID: 13861860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.